Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 3/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | STS | P08842 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31223970 | 0.92 | PDE4B (0.37) | USP30PDE4BRORCNR1H2TSHR | |
| SCHEMBL31224059 | 0.86 | RORC (0.36) | USP30PDE4BRORCNR1H2HSP90AA1 | |
| SCHEMBL31224000 | 0.86 | NR1H2 (0.39) | USP30PDE4BRORCNR1H2IDO1 | |
| SCHEMBL31224161 | 0.86 | USP30 (0.33) | USP30PDE4BRORCNR1H2HSP90AA1 | |
| SCHEMBL31224528 | 0.85 | PDE4B (0.34) | USP30HTTPDE4BRORCHSP90AA1 | |
| SCHEMBL31224256 | 0.85 | USP30 (0.35) | USP30PDE4BRORCIDO1GPR119 | |
| SCHEMBL31224149 | 0.85 | PDE4B (0.34) | USP30HTTPDE4BRORCHSP90AA1 | |
| SCHEMBL31224343 | 0.85 | PDE4B (0.39) | USP30PDE4BNR1H2IDO1 | |
| SCHEMBL31224282 | 0.84 | IDO1 (0.35) | USP30PDE4BRORCNR1H2IDO1 | |
| SCHEMBL31223968 | 0.83 | RORC (0.35) | RORCNR1H2HSP90AA1HSP90AB1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024259171-A9 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2025-01-23 | — | — | WO | disclosed |
| US-20250011291-A1 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| WO-2024259171-A2 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011291-A1 | KEAP1 INHIBITORS AND USES THEREOF | KEAP1, NFE2L2, NQO1 | USP30 757/4885HTT 1273/4885PDE4B 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.